Prediction confusion matrix for 13 subtypes determined by 10-fold cross-validation
. | Real . | . | . | . | . | . | . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Confusion matrix . | c-ALL/pre-B-ALL . | Pro-B-ALL with t(11q23) . | Mature B-ALL with t(8;14) . | T-ALL . | AML with t(15;17) . | AML with t(8;21) . | AML with inv(16) . | AML with t(11q23) . | AML with complex karyotype . | AML normal/other . | CLL . | CML . | Nonleukemia . | ||||||||||||
| c-ALL/pre-B-ALL | 76 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Pro-B-ALL with t(11q23) | — | 25 | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Mature B-ALL with t(8;14) | 1 | — | 10 | — | — | — | — | — | — | 1 | — | — | — | ||||||||||||
| T-ALL | — | — | — | 28 | — | — | — | — | 1 | — | — | — | — | ||||||||||||
| AML with t(15;17) | — | — | — | — | 42 | — | — | — | — | — | — | — | — | ||||||||||||
| AML with t(8;21) | — | — | — | — | — | 36 | 1 | — | — | — | — | — | — | ||||||||||||
| AML with inv(16) | — | — | — | — | — | — | 48 | — | — | — | — | — | — | ||||||||||||
| AML with t(11q23) | — | — | — | — | — | — | — | 42 | — | 4 | — | — | 1 | ||||||||||||
| AML with complex karyotype | — | — | — | — | — | 1 | — | — | 66 | 4 | — | — | — | ||||||||||||
| AML normal/other | 4 | 1 | 2 | 4 | — | 1 | — | 4 | 8 | 359 | 1 | 2 | 2 | ||||||||||||
| CLL | — | — | — | — | — | — | — | — | — | — | 44 | — | — | ||||||||||||
| CML | — | — | — | — | — | — | — | 1 | — | — | — | 73 | — | ||||||||||||
| Nonleukemia | 1 | — | — | — | — | — | — | — | — | 1 | — | — | 42 | ||||||||||||
| Total | 82 | 26 | 12 | 32 | 42 | 38 | 49 | 47 | 75 | 369 | 45 | 75 | 45 | ||||||||||||
. | Real . | . | . | . | . | . | . | . | . | . | . | . | . | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Confusion matrix . | c-ALL/pre-B-ALL . | Pro-B-ALL with t(11q23) . | Mature B-ALL with t(8;14) . | T-ALL . | AML with t(15;17) . | AML with t(8;21) . | AML with inv(16) . | AML with t(11q23) . | AML with complex karyotype . | AML normal/other . | CLL . | CML . | Nonleukemia . | ||||||||||||
| c-ALL/pre-B-ALL | 76 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Pro-B-ALL with t(11q23) | — | 25 | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||
| Mature B-ALL with t(8;14) | 1 | — | 10 | — | — | — | — | — | — | 1 | — | — | — | ||||||||||||
| T-ALL | — | — | — | 28 | — | — | — | — | 1 | — | — | — | — | ||||||||||||
| AML with t(15;17) | — | — | — | — | 42 | — | — | — | — | — | — | — | — | ||||||||||||
| AML with t(8;21) | — | — | — | — | — | 36 | 1 | — | — | — | — | — | — | ||||||||||||
| AML with inv(16) | — | — | — | — | — | — | 48 | — | — | — | — | — | — | ||||||||||||
| AML with t(11q23) | — | — | — | — | — | — | — | 42 | — | 4 | — | — | 1 | ||||||||||||
| AML with complex karyotype | — | — | — | — | — | 1 | — | — | 66 | 4 | — | — | — | ||||||||||||
| AML normal/other | 4 | 1 | 2 | 4 | — | 1 | — | 4 | 8 | 359 | 1 | 2 | 2 | ||||||||||||
| CLL | — | — | — | — | — | — | — | — | — | — | 44 | — | — | ||||||||||||
| CML | — | — | — | — | — | — | — | 1 | — | — | — | 73 | — | ||||||||||||
| Nonleukemia | 1 | — | — | — | — | — | — | — | — | 1 | — | — | 42 | ||||||||||||
| Total | 82 | 26 | 12 | 32 | 42 | 38 | 49 | 47 | 75 | 369 | 45 | 75 | 45 | ||||||||||||
N = 937 patients and controls. Classifications made on the basis of routine diagnostics, including cytomorphology, cytochemistry, immunophenotyping, cytogenetics, and molecular genetics, are given in columns. Predicted classifications using gene expression profiling are given in rows. Thus, 891 (95.1%) of 937 patients were correctly classified.
— indicates no case.